TY - JOUR T1 - Comparison of Glycemic Control between Intensive Insulin Regimen and Continuous Subcutaneous Insulin infusion: A Meta-Analysis Report of Type-1 Diabetics from Randomized Controlled Trials JF - medRxiv DO - 10.1101/2020.06.01.20119693 SP - 2020.06.01.20119693 AU - Kamran Mahmood Ahmed Aziz AU - Abdullah Othman Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/02/2020.06.01.20119693.abstract N2 - Achieving glycemic control and targets are challenging in type-1 diabetes management. To achieve this, intensive insulin therapy or multiple daily injections (MDI) and continuous subcutaneous insulin infusion (CSII) or pump therapy have been used in various health care settings. However, there has been a debate on their superiority. Some of researchers have recommended MDI, while others SCII. We compared MDI with CSII by a literature search. We have conducted mata-analysis for MDI and CSII on ten randomized controlled trials on 809 type-1 diabetics 809, MDI (N = 394) or CSII (N = 415). Heterogeneity between trials was quantified by conventional Q-statistic (Cochran’s heterogeneity statistic) and Higgins I2 statistic with 0-40% representing negligible heterogeneity, 30-60% moderate heterogeneity, 50-90% substantial heterogeneity and 75-100% considerable heterogeneity. tau-squared (τ2) was used to observe between-study random-effects variance. Meta Analyst software was used to analyze the data and to conduct meta-analysis. SPSS was used to analyze HbA1c student’s t-test for MDI and CSII. A random-effect analysis ((DerSimonian-Laird method) performed on ten studies found that the percentage of HbA1c was lower in patients receiving CSII compared with those receiving MDI; standardized mean difference (SMD) was 0.441, 95% confidence interval 0.267 to 0.616, p < 0.001; equivalent to a difference of 0.39%, favoring CSII. I2 statistic was 20.9; τ2 = 0.016; Q = 11.378 with df = 9, indicating that heterogeneity was not significant (heterogeneity p-value = 0.251). Patients on CSII demonstrated significantly lower values (8.2±0.72 versus 7.73±0.72; p-value < 0.001 respectively). This statistical and meta-analysis favors the usage of insulin pump therapy. We concluded that patient centered approach should be used while selecting the patients for insulin pump (CSII) or MDI.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received and no organization funded this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB and Research Committee of Aseer Endocrine and Diabetes CenterAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData fro RCT ER -